Moderna Cancer Vaccine Data Accepted for ESMO Presentation
The company will share trial results on its personalized cancer vaccine at the upcoming ESMO Congress in October.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Is now a good time for individual investors to trade stocks based on clinical trial news?
Moderna shares rose 11.15% to $171.21 on September 21, 2026, after the company announced that three abstracts regarding its personalized cancer vaccine were accepted for the ESMO Congress. Data from the Phase 3 INTerpath-001 trial will be revealed at the event.
Why it matters
Investors and the public are tracking these findings as they provide insight into the potential efficacy of personalized immunotherapy. The presentation at the ESMO Congress represents a critical update in the clinical progression of this new treatment approach.
The upcoming presentation includes Phase 3 data from the INTerpath-001 trial, which evaluates a personalized cancer vaccine in combination with Keytruda compared to Keytruda monotherapy. These results are preliminary until their formal presentation at the ESMO Congress.
The players
Moderna
A biotechnology company focused on mRNA-based therapeutics and vaccines for infectious diseases and oncology.
ESMO Congress
An international medical oncology conference where researchers present new clinical trial results.
The details
The treatment being studied, intismeran autogene, is a personalized cancer vaccine designed to stimulate the immune system to recognize and target specific tumor markers. It is being tested in conjunction with Keytruda, a well-known immunotherapy agent that helps immune cells detect cancer. By combining these therapies, researchers aim to improve the body's ability to destroy malignant cells more effectively than current standard monotherapies.
Timeline
August 19, 2026: Moderna stock reached an intraday high near $196.
September 21, 2026: Shares rose 11.15% to $171.21.
October 23 to October 27, 2026: The ESMO Congress will take place in Madrid.
October 24, 2026: Phase 3 data from the INTerpath-001 trial will be presented.
Health Landscape
The presentation of the INTerpath-001 trial data is a major milestone in the development of personalized mRNA cancer vaccines. It follows a shift in medical research toward combination therapies that pair targeted vaccine technology with existing immune checkpoint inhibitors.
This development indicates that Phase 3 trial data will soon be available to help the medical community understand the role of personalized vaccines in cancer treatment. Patients interested in these emerging therapies should discuss the latest findings with their oncologist.
The takeaway
The upcoming release of Phase 3 trial results marks a critical step forward in evaluating the potential for personalized mRNA vaccines. Readers should follow updates from the ESMO Congress to understand how these findings might eventually influence future treatment standards.
What happens next
Moderna will host a live-streamed investor session on October 24, 2026, which will be accessible for 30 days after the event.
Further reading
Learn more about the latest developments in immunotherapy and clinical research by visiting the Cancer section.
Live Poll
Is now a good time for individual investors to trade stocks based on clinical trial news?
